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Objectives.ComparethePlanBlevonorgestrel(LNG)areaundertheconcentration-timecurve(AUC12)priortoandwithefavirenz
(EFV). Design. Prospective, open-label, single-arm, equivalence study. Methods. Healthy HIV-negative subjects underwent 12hr
intensive pharmacokinetic (PK) sampling following single dose LNG alone and after 14 days of EFV. Geometric means, Geometric
Mean Ratios, and 90% conﬁdence intervals (CI) are reported for PK Parameters. T-tests were utilized. Clinical parameters and
liver function tests (LFTs) were assessed. Results. 24 women enrolled and 21 completed the study. With EFV, LNG AUC12 was
reduced 56% (95% CI: 49%, 62%) from 42.9 to 17.8ng∗hr/mL, and maximum concentration (Cmax) was reduced 41% (95% CI:
33%, 50%) from 8.4 to 4.6ng/mL. LNG was well tolerated with no grade 3 or 4 treatment-related toxicities. Conclusions.E F V
signiﬁcantly reduced LNG exposures. Higher LNG doses may be required with EFV. These results reinforce the importance of
eﬀective contraception in women taking EFV.
1.Introduction
The majority of women with human immunodeﬁciency
virus −1 (HIV) are of reproductive age and may use an
efavirenz- (EFV-) containing antiretroviral (ARV) regimen
[1, 2]. EFV is a nonnucleoside reverse transcriptase inhibitor
(NNRTI) indicated in combination with other antiretroviral
agents for the treatment of HIV [3]. EFV is an FDA
pregnancy category D drug based on animal studies and
human case reports of fetal neural tube defects [3–6]. Thus,
preventing pregnancy is critical in HIV-infected women
receiving EFV.
Pregnancy rates for HIV-infected women range from 6.0
to 8.2 pregnancies per 100 person-years, and in 2001, 49%
of all pregnancies in the United States were unintended [7–
9]. Women with HIV not desiring pregnancy are advised
to use dual methods of contraception to prevent pregnancy
and HIV transmission to their partners. Some women use
emergency hormonal contraception to prevent pregnancy
after unprotected sex or contraceptive failure (condom
breakage).
Plan B is a levonorgestrel- (LNG-) containing emergency
contraceptive pill indicated for pregnancy prevention fol-
lowing unprotected intercourse or a known or suspected
contraceptive failure [10]. It is taken as soon as possible
within 72 hours after unprotected intercourse either as
a single dose (LNG 1.5mg) or as two doses (0.75mg)
taken twelve hours apart. LNG use for emergency hormonal
contraception has been shown to reduce pregnancy rates
by 85% [11]. The mechanism of action of Plan B is not
fully elucidated. It may inhibit ovulation, fertilization, or
implantation [10, 11]. The minimum eﬀective LNG plasma
concentration is unknown.
Few data are available on the pharmacokinetics (PK) of
progesterone-based contraceptives with NNRTIs. A study of
depomedroxyprogesterone acetate (DMPA) depot injections
in HIV-infected women on antiretroviral therapy revealed
no signiﬁcant change in plasma levels of MPA or EFV,2 Infectious Diseases in Obstetrics and Gynecology
nevirapine, or nelﬁnavir [12]. However, in a study of EFV
and the combination oral contraceptive pill OrthoTriCyclen-
Lo and OrthoCyclen (25mcg ethinyl estradiol plus 0.18–
0.25mg norgestimate), LNG area under the concentra-
tion time curve from 0 to 12 hours (AUC12), maximum
concentration (Cmax), and minimum concentration (Cmin)
were decreased by 80%, 83%, and 86%, respectively [13].
A case of contraceptive failure with ectopic pregnancy in
an HIV-infected woman occurred with the etonogestrel
contraceptive implant and EFV [14]. No PK interaction
studies of Plan B and concomitant efavirenz have been
performed [14].
2. Methods
2.1. Subjects. Subjects were HIV-seronegative women ages
18–45 years with normal body mass index and no recent
use of hormonal contraceptive agents (oral or vaginal
hormonal contraception use within 60 days or injectable
hormonal contraception use within 180 days of study
entry; subjects with Mirena IUD were excluded) or other
medications/therapies known to interact with EFV. Subjects
who had not undergone surgical sterilization used 2 nonhor-
monal types of contraception throughout the study period
and for 2 weeks following study completion.
The protocol was approved by the institutional review
board at participating sites, and informed consent was
obtained from each woman before participation.
2.1.1. Study Design. This was a prospective, open-label,
single-arm, two-period, PK equivalence study. The primary
objective was to compare Plan B LNG AUC12 p r i o rt oa n d
during steady-state EFV. Secondary objectives included (1)
characterization of other LNG plasma PK parameters, (2)
assessment of the safety and tolerability of coadministration
of Plan B and EFV, and (3) evaluation of potential eﬀects
of LNG on EFV AUC24 with comparison to previous data
in HIV+ women. Study participants received LNG 0.75mg
at time 0 and 12 hours at baseline (visit 1-day 0) and after
steady state EFV dosing (visit 2-day 17). Subjects were begun
on EFV 600mg at bedtime on empty stomach 72 hours
after visit 1 for a total duration of 14 days. Participants
fasted at least 12 hours prior to the PK study visits and
ate a standardized breakfast with LNG dosing (600kcal;
15% protein, 30% fat, and 55% carbohydrates). Serial blood
(plasma) sampling for LNG PK analysis was performed after
LNG dosing at 0 (predose), 2, 3, 4, 6, 8, 10, and 12 hours at
Visit 1 and 2. Blood (plasma) sampling for EFV PK analysis
was performed prior to LNG dose, 6 and 12 hours after LNG
dose at visit 2 only (corresponding to approximately 10, 16,
and 22 hours from EFV dosing). Relevant clinical adverse
events were assessed at study and 4 telephone visits (study
days 4, 11, 16, and 20–28). Safety and laboratory proﬁles and
pregnancy testing were performed at screening and visits 1,
2 (LFT’s only), and 3. EFV adherence was assessed by subject
self-report at telephone visits approximately 7 and 17 days
after EFV was initiated.
2.2. Bioanalyses. LNG plasma concentrations were deter-
mined with a liquid chromographic assay with MS/MS
detection linear in the range of 50–25000pg/mL. Accuracy
and precision were within ±11% using a 0.5mL plasma
sample. EFV plasma concentrations were determined using
a validated HPLV/UC method linear in the range of 20–
20,000ng/mL. Accuracy and precision were within ±15%
with 0.2mL plasma. Samples were frozen and shipped to
PPD, Inc. for LNG analysis and University of Colorado
Pharmacology lab for EFV analysis.
2.3. Data Analyses. Sample size calculations assumed that
expected LNG AUC12 was 123.1ng∗hr/mL with a standard
d e v i a t i o no f5 0 . 1[ 15]. Assuming equal variances and a
modest correlation of 0.5, the standard deviation of the
diﬀerence is also 50.1. 18 subjects were required to detect a
diﬀerenceof49.2(a40%change)inLNGAUC12 usingatwo-
sided,pairedt-testwithasigniﬁcancelevelof0.05and97.5%
power.Toaccountfordrop-outs,weenrolled24participants.
LNG PK was determined by noncompartmental meth-
ods (WinNonLin V5.2.1, Pharsight Corporation, Mountain
V i e w ,C A ) .L N GA U C 12 was calculated with the linear-
log trapezoidal rule and LNG Cmin, Cmax,a n dt i m et o
Cmax (Tmax) determined visually. LNG half-lives (t1/2)w e r e
calculated as 0.693 divided by λz, where λz was the terminal
elimination rate constant. LNG total apparent oral clearance
(CL/F) was determined as dose divided by AUC12.A p p a r e n t
volume of distribution (V/F) was determined by CL/F
divided by λz.
AposthocBayesianapproach(NONMEMvVI)wasused
to estimate each subject’s EFV AUC24 based on the three
measured EFV levels. The estimated AUC24 was compared
to data from a previous PK study of HIV+ women using a
2-sample t-test [16].
For the primary hypothesis, equivalence was deﬁned as a
decrease of less than 40% LNG AUC12 after addition of EFV
based on previous studies utilizing a 40% diﬀerence in con-
traceptive steroid hormone AUC as that which is clinically
relevant [12]. Percent change was calculated from the raw
(untransformed) data. The null hypothesis of equivalence
was rejected if the corresponding 95% conﬁdence interval
included values ≤40%.
PK data were log transformed. Point estimates and 90%
conﬁdence intervals for geometric means of LNG AUC12,
Cmax, Cmin, V/F and CL/F, and t1/2 were determined for LNG
dosed alone and with EFV. Geometric mean ratios (GMR)
for LNG AUC12, Cmax,a n dCmin with versus without EFV
were calculated. Relevant clinical adverse events and liver
functiontestelevationsweresummarized.Pairedt-testswere
used.
3. Results
3.1. Demographics. Twenty-four women enrolled, and 23
subjects commenced study visits and treatments. Three sub-
jects discontinued; 2 for adverse events and 1 for personal
reasons. Evaluable PK data was generated for 21 women who
had a mean age of 31 years (range 21–45) and BMI of 27Infectious Diseases in Obstetrics and Gynecology 3
Table 1: Estimated LNG PK parameters.
PK parameter Percent change raw scale (95% CI) LNG GM (90% CI) LNG + EFV GM (90% CI) P value GMR (90% CI)
AUC12 (ng∗hr/mL) −56% (−49%, −62%) 42.9 (38.0, 48.5) 17.8 (15.5, 20.5) <0.0001 0.42 (0.36, 0.48)
Cmax (ng/mL) −41% (−33%, −50%) 8.4 (7.6, 9.3) 4.6 (4.0, 5.4) <0.0001 0.55 (0.49, 0.63)
Cmin (ng/mL) −67% (−59%, −74%) 2.04 (1.7, 2.3) 0.6 (0.5, 0.7) <0.0001 0.31 (0.26, 0.36)
V/F (L) 110% (−155%, 176%) 144 (120, 173) 256 (217, 301) 0.0001 —
CL/F (L/hr) 260% (159%, 364%) 9.7 (8.0, 11.6) 32.1 (27.6, 37.3) <0.0001 —
t1/2 (hr) −34% (−17%, −55%) 10.3 (8.1, 13.2) 5.5 (4.6, 6.7) 0.0001 —
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Figure 1: Mean plasma concentration versus time proﬁle for
LNG. Mean (±SD) levonorgestrel concentration-time proﬁle in 21
healthy volunteers administered alone (red) and after 14 days of
pretreatment with efavirenz (blue).
(range 21–35). The majority of subjects were white (62%),
and 24% were Latina and 10% Black. Contraception use
included condoms, spermicide, diaphragm, abstinence, and
intrauterine device.
3.2. LNG and EFV Pharmacokinetics. The estimated percent
decrease in LNG AUC12 with EFV was 56% (Table 1), and
the corresponding 95% conﬁdence interval (49%, 62%)
excluded a change of ≤40% (P<0.0001), such that the
equivalence hypothesis was rejected. A decrease in LNG
AUC12 of >40% was observed in 90.5% (95% CI: 0.70%,
0.99%) of women. LNG Cmax and Cmin GMR were 0.55
and 0.31, respectively. LNG concentration time curves are
shown in Figure 1. The geometric mean EFV AUC24 in com-
bination with LNG was 69597ng∗hr/mL. (90% CI 27629,
175316ng∗hr/mL). This value was compared to a previous
study of EFV PK in HIV-infected females which demon-
s t r a t e da nE F Vg e o m e t r i cm e a nA U C 24 of 61361ng∗hr/mL
(90% CI 19076, 197379ng∗hr/mL) (P value = 0.35) [15].
Study participants had a >95% adherence with EFV dosing,
and all had detectable EFV levels.
3.3. Safety and Tolerability. Headache, abdominal pain, diar-
rhea, and menstrual cycle changes were the most common
adverse events occurring in >10% of subjects after Plan B
dosing alone. The incidence of abdominal pain, diarrhea,
and menstrual cycle changes was decreased, while incidence
of fatigue was increased with EFV. The occurrence of rash,
pruritus, abnormal dreams, and insomnia was similar to
previous studies of EFV [3]. Changes in LFT’s were rare
and resolved with discontinuation of EFV. Adverse events
were mild (Grade 1) to moderate (Grade 2) in majority and
were resolved at follow-up visits. Two subjects discontinued
study secondary to adverse events. One subject had a grade 2
rash likely related to study treatment (EFV) and resolved at
follow-up visits. One subject had grade 3 syncope not related
to study treatment and attributed to a vasovagal reaction
with phlebotomy.
4. Discussion
Data are limited regarding the use of hormonal contra-
ception in HIV-infected women on antiretroviral therapy.
Interactions have been described between steroid hormones
and both protease inhibitors and NNRTI which could lead
to decreased protection from pregnancy or increased contra-
ceptive side eﬀects [17]. Previous studies have focused pre-
dominantly on combined oral contraceptive pills, injectable
DMPA, and one small study evaluated PK with the transder-
mal contraceptive patch [12, 13, 18]. Women taking EFV are
speciﬁcally advised to avoid pregnancy due to this agents’
potential role in fetal neural tube defects [3, 19]. Thus,
emergencyhormonalcontraception,likePlanB,maybeeven
more important for these women.
We sought to evaluate the eﬀect of EFV on plasma
concentration of LNG in Plan B in healthy HIV-negative
women. We found that pretreatment with EFV for 14 days
was associated with a 56%, 41%, and 67% decrease in LNG
AUC12, Cmax,a n dCmin,r e s p e c t i v e l y .
The mechanism for this interaction is likely EFV induc-
tion of LNG metabolism. EFV is an inducer of CYP3A
and uridine-diphosphate glucuronosyl transferases (UGTs)
in vivo [3]. LNG exposures are reduced approximately
40% with the anticonvulsants phenytoin and carbamazepine
(inducers of CYP3A) and 19% with lamotrigine (an inducer
of glucuronidation enzymes) [20, 21]. A study of rifampin
andoralcontraceptiondemonstratedconsiderablereduction
in contraceptive hormone levels; however, ovulation sup-
pression persisted [22].4 Infectious Diseases in Obstetrics and Gynecology
These ﬁndings may have important ramiﬁcations with
regard to the eﬃcacy of Plan B when taken with this
ARV. However, the clinical relevance of this ﬁnding is
unclear as the minimal eﬀective LNG plasma concentration
is unknown. We did not monitor for ovulation which
may signal failed contraception. It is possible the alternate
Plan B single dosing of LNG 1.5mg would mitigate this
eﬀect; however, this is unlikely given the magnitude of
our observed diﬀerence. Further clinical studies of Plan B
and EFV are thus needed to inform providers of potential
need for Plan B dosing adjustments for these women.
HIV providers’ role in providing family planning services
including contraception and preconception counseling is
signiﬁcant given the inherent complexities with HIV and
antiretroviral therapy.
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